Merck KGAA Invests €260m In Production Value Chain in China
German group Merck has inaugurated a major new pharmaceutical plant and announced a further investment in China, where it sees opportunities in essential drugs amid rising demand as the country broadens its basic healthcare coverage and its population ages.
You may also be interested in...
Problems With Alternative Levothyroxine In France Force Merck To Switch Back To Original
French patients who have experienced adverse reactions to a new formulation of Merck KGaA’s hypothyroidism drug Levothyrox are to be given temporary access to the original formulation, pending the availability of other brands of levothyroxine. Merck says the vast majority of patients have had no problems with the new version.
Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
Erbitux TAILOR-Made For China First-Line mCRC Market, But Brand Recognition Merck’s Real Goal?
Merck's plans to penetrate the Chinese market further with its anti-EGFR cancer therapy Erbitux have received a boost with the Phase III TAILOR trial showing significant benefits when used first-line in metastatic colorectal cancer in this population.